Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A method of treatment <u>for mastalgia</u>, comprising administering 4-hydroxy tamoxifen percutaneously to <u>the breasts of</u> a patient having mastalgia, at a dose of at least 1.5 mg/day.
- 2. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is in a vehicle containing a penetration enhancer.
- 3. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a racemic blend of *trans* and *cis* isomers.
- 4. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is a *trans* isomer.

Claim 5 (Canceled)

- 6. (Original) A method according to claim 1, wherein greater than about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
- 7. (Original) A method according to claim 1, wherein greater than about 1 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
- 8. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic gel.
- 9. (Original) A method according to claim 8, wherein said hydroalcoholic gel comprises ethyl alcohol, isopropyl myristate, and hydroxypropylcellulose.
- 10. (Original) A method according to claim 1, wherein said 4-hydroxy tamoxifen is formulated in an alcoholic solution.

- 11. (Original) A method according to claim 1, wherein said mastalgia is cyclical.
- 12. (New) A method according to claim 1, wherein about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
- 13. (New) A method according to claim 1, wherein about 1 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
- 14. (New) A method according to claim 1, wherein about 2 mg of said 4-hydroxy tamoxifen is administered to said patient per day.